Bayer AG
Investor Relations
51368 Leverkusen
Germany
www.investor.bayer.com

Investor News

Not intended for U.S. and UK Media

Bayer and Trius Therapeutics to develop and commercialize new antibiotic for specific skin infections and pneumonia

Leverkusen, July 27, 2011 – Bayer HealthCare and Trius Therapeutics, Inc., San Diego, California, today announced that they have signed an exclusive agreement to develop and commercialize Trius' lead antibiotic, torezolid phosphate (torezolid), in China, Japan and all other countries in Asia, Africa, Latin America and the Middle East, excluding North and South Korea. The companies agreed to collaborate on the development of the compound, which is already in Phase III clinical development in the US and the EU, in acute bacterial skin and skin structure infections (ABSSSI) and pneumonia caused by Gram-positive bacteria both globally and in the Bayer territory. Trius retains full development and commercialization rights for the United States, Canada and the European Union.

Bayer will pay Trius 25 million US Dollar upfront and will partly bear future development costs required for global approval in ABSSSI and pneumonia. In addition, Trius is eligible to receive up to 69 million US Dollar upon the achievement of certain development, regulatory and commercial milestones and will receive double-digit royalties on net sales of torezolid in the licensed territory.

"Bacterial infectious diseases represent one of the largest therapeutic areas in China and continue to grow rapidly there and in other emerging markets. This collaboration is a key element in our strategy of bringing innovative medicines to patients, especially in emerging markets", said Dr. Jörg Reinhardt, Chairman of the Board of Management of Bayer HealthCare.

"Bayer's commitment to the infectious disease area and their depth and breadth of experience in these markets makes them an ideal partner for Trius", said Jeffrey Stein, Ph.D., President and CEO of Trius.

About Torezolid Phosphate (Torezolid)
Torezolid phosphate is an IV and orally administered second generation oxazolidinone in Phase III clinical development in the US and the EU for the treatment of acute bacterial skin and skin structure infections, the first such trial to be initiated under a Special Protocol Assessment (SPA).

Acute bacterial skin and skin structure infections (ABSSSI), a new FDA classification for complicated skin and skin structure infections (cSSSI), are a significant and growing problem throughout the world. ABSSSI are infections that involve deeper tissue or require surgical intervention (e.g. cellulitis, major cutaneous abscesses, and infected wounds) or are associated with a significant underlying disease (e.g. diabetes or systemic immunosuppression) that complicates response to therapy. A variety of pathogens may be identified in ABSSSI but the two most common Gram-positive pathogens are *Staphylococcus aureus* and *Streptococcus pyogenes*. The significant increase in the incidence of methicillin-resistant *Staphylococcus aureus* (MRSA) in community as well as hospital acquired infections has resulted in a need for therapy of ABSSSI that is effective against MRSA.

About Trius Therapeutics
Trius Therapeutics is a biopharmaceutical company focused on the discovery, development and commercialization of innovative antibiotics for life-threatening infections. Trius holds an exclusive license to torezolid phosphate for territories outside of North and South Korea from Dong-A Pharmaceuticals. In addition to the company's torezolid phosphate clinical program, it is currently conducting three preclinical programs using its proprietary discovery platform to develop antibiotics to treat infections caused by Gram-negative bacteria. For more information, visit www.triusrx.com.

About Bayer HealthCare
The Bayer Group is a global enterprise with core competencies in the fields of health care, nutrition and high-tech materials. Bayer HealthCare, a subgroup of Bayer AG with annual sales of EUR 16.913 billion (2010), is one of the world's leading, innovative companies in the healthcare and medical products industry and is based in Leverkusen, Germany. The company combines the global activities of the Animal Health, Consumer Care, Medical Care and Pharmaceuticals divisions. Bayer HealthCare's aim is to discover and manufacture products that will improve human and animal health worldwide. Bayer HealthCare has a global workforce of 55,700 employees (Dec 31, 2010) and is

represented in more than 100 countries. Find more information at www.bayerhealthcare.com.

Bayer AG, Investor Relations contacts:

Dr. Alexander Rosar (+49-214-30-81013)
Dr. Juergen Beunink (+49-214-30-65742)
Peter Dahlhoff (+49-214-30-33022)
Judith Nestmann (+49-214-30-66836)
Dr. Olaf Weber (+49-214-30-33567)
Fabian Klingen (+49-214-30-35426)
Ute Menke (+49-214-30-33021)

Forward-Looking Statements
This release may contain forward-looking statements based on current assumptions and forecasts made by Bayer Group or subgroup management. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here. These factors include those discussed in Bayer's public reports which are available on the Bayer website at www.bayer.com. The company assumes no liability whatsoever to update these forward-looking statements or to conform them to future events or developments.